| Summary: | Thesis (M.Sc.)--Memorial University of Newfoundland, 2008. Pharmacy Includes bibliographical references. Long term, localized continuous release of Endostatin (END) in the vicinity of tumour bed represents a new strategy for neoplastic treatment. The main reason of localization is to maximize the therapeutic outcome and at the same time to reduce the toxic effects on the surrounding tissues due to the exposure to the angiogenesis inhibitory effect of END. The main objective of this study was to design and formulate a biodegradable and biocompatible polymeric device for delivering END at a sustained and constant rate, and at a concentration within its therapeutic window by utilizing the osmotic release mechanism. The new device was prepared by mixing of END with osmotically active excipients and incorporate the mixture as solid particles within a rubbery polyermic matrix. The results demonstrated that this new device achieved a constant and sustained release rate for END for a certain period.
|
|---|